BioPharmSignal logoBioPharmSignal

Biotech News

Enlivex Announces Cost Reduction Plan to Focus Resources on Phase 2b Trial of Allocetra™ in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis

Enlivex Therapeutics (ENLV)Enlivex TherapeuticsClinical readout

Non-clinical R&D activities to be wound down; resources to be focused on executing the Phase 2b trial

Workforce reduced by approximately 60%; management and CEO salaries reduced

<li style="margin-top:0in;...

Related news

ENLVEnlivex Therapeutics2026-10-28 13:00 EST

Enlivex Announces Randomization of 135 Patients in Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis

ENLVEnlivex Therapeutics2026-11-02 14:00 EST

Enlivex Announces Favorable 12-Month Topline Data from Phase I/IIa Allocetra Trial, Demonstrating Durable Treatment Response

BMYBMYBristol-Myers Squibb Company2026-10-12 10:50 EST

Bristol Myers Squibb Announces Phase 3 ALOFT-IPF Trial Evaluating Admilparant in Adults with Idiopathic Pulmonary Fibrosis Met Primary Endpoint

SLSSELLAS Life Sciences Group, Inc.2026-10-28 12:35 EST

SELLAS Life Sciences Reaches 80th Event in Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia

BNTXBioNTech2026-10-26 09:00 EST

BioNTech and DualityBio Announce Topline Results of the DYNASTY-Breast02 Global Phase 3 Clinical Trial Evaluating Trastuzumab Pamirtecan in HR+/HER2-low Metastatic Breast Cancer

SLSSELLAS Life Sciences Group, Inc.2026-11-04 14:00 EST

SELLAS Life Sciences to Present Positive Phase 2 Data Demonstrating Encouraging Response and Survival Outcomes with SLS009 Combination in High-Risk AML at ASH 2026

BMYBMYBristol-Myers Squibb Company2026-10-26 07:30 EST

Izalontamab Brengitecan (Iza-Bren) Doubles Median Progression-Free Survival in Patients with Previously-Treated EGFR-Mutated Non-Small Cell Lung Cancer Compared to Chemotherapy in the Phase 3 PANKU-Lung01 Study

CMPXCompass Therapeutics2026-10-24 08:15 EST

Compass Therapeutics Announces Publication of Phase 2/3 COMPANION-002 Results for Tovecimig in the Journal of Clinical Oncology and Oral Presentation at ESMO 2026

BNTXBioNTech2026-10-22 10:45 EST

BioNTech Advances Phase 3 Clinical Trial of Pumitamig in Combination with Gilead’s TROP2-Directed ADC Sacituzumab Govitecan in Triple-Negative Breast Cancer

MDNAMedicenna Therapeutics Corp.2026-10-05 13:00 EST

Medicenna Announces Oral Presentation of Topline Data from the Phase 1/2 ABILITY-1 Study of MDNA11 at SITC 2026

View all latest news

Enlivex Therapeutics

Enlivex Therapeutics is an immunotherapy company focused on macrophage reprogramming and inflammation-related disease. Its story is centered on harnessing innate immunity to address hard-to-treat conditions.

Recent company news

ENLVEnlivex Therapeutics2026-11-02 14:00 EST

Enlivex Announces Favorable 12-Month Topline Data from Phase I/IIa Allocetra Trial, Demonstrating Durable Treatment Response

ENLVEnlivex Therapeutics2026-10-28 13:00 EST

Enlivex Announces Randomization of 135 Patients in Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis

ENLVEnlivex Therapeutics2026-10-28 13:00 EST

Enlivex Announces Randomization of 135 Patients in Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis

ENLVEnlivex Therapeutics2026-10-27 13:00 EST

Enlivex Announces Receipt of Delisting Notice from Nasdaq; Intends to Appeal

ENLVEnlivex Therapeutics2026-10-27 13:00 EST

Enlivex Announces Receipt of Delisting Notice from Nasdaq; Intends to Appeal

Stock data

Close
1.27 USD
Market cap
204.87M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States